ScreenerHero

CMMB Chemomab Therapeutics Ltd.

NAS · US · Healthcare · Biotechnology · chemomab.com
1.370USD-2.14%Mkt Cap: 10.04M $P/E: —

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.04M USD
Enterprise Value3.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.99M USD
Revenue/Share—
Last Price1.370 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-46.67
PEG—
EV/EBITDA-0.44
EV/Revenue—
P/S—
P/B1.17
EPS (TTM)-1.04
EPS (Forward)-0.03
52W Range
1.05113% of range3.580
52W High3.580 USD
52W Low1.051 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.93%
ROA-65.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.13M USD
CapEx (TTM)3.00K USD
FCF Margin—
FCF Yield-61.66%
Net Debt-6.69M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.00
Current Ratio6.41
Quick Ratio6.41
Book Value/Sh1.20 USD
Cash/Share0.92 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateAug 26, 2025
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+265.0%
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.7.33M
Float6.06M
Insiders12.19%
Institutions19.07%
Short Interest
Short Ratio0.7d
Short % Float1.15%
Short % Out.1.12%
Shares Short81.95K
Short (prev mo.)113.16K
Technical
SMA 502.115 (-35.2%)
SMA 2001.812 (-24.4%)
Beta0.74
S&P 52W Chg16.45%
Avg Vol (30d)141.02K
Avg Vol (10d)218.42K
Technical Indicators
RSI (14)30.4
MACD-0.2448
MACD Signal-0.1380
MACD Hist.-0.1068
BB Upper3.160 USD
BB Middle2.050 USD
BB Lower0.9396 USD
BB Width108.33%
ATR (14)0.2223 USD
Vol Ratio (20d)0.06x